Lisocabtagene Maraleucel for Richter's Transformation—A Case Series
ABSTRACT Introduction Richter's transformation (RT) from chronic lymphocytic leukemia (CLL) to lymphoma carries poor prognosis. This case series examines the efficacy of lisocabtagene maraleucel (liso‐cel) in six RT patients, highlighting the impact of concurrent ibrutinib therapy. Methods Six...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-04-01
|
| Series: | eJHaem |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jha2.70011 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850179486945902592 |
|---|---|
| author | Courtney J. Smith Anmol Goyal Brian R. Smith Dasom Lee Alexandria Jensen Jonathan Alexander Melody Smith Matthew Frank Saurabh Dahiya David Miklos Sushma Bharadwaj |
| author_facet | Courtney J. Smith Anmol Goyal Brian R. Smith Dasom Lee Alexandria Jensen Jonathan Alexander Melody Smith Matthew Frank Saurabh Dahiya David Miklos Sushma Bharadwaj |
| author_sort | Courtney J. Smith |
| collection | DOAJ |
| description | ABSTRACT Introduction Richter's transformation (RT) from chronic lymphocytic leukemia (CLL) to lymphoma carries poor prognosis. This case series examines the efficacy of lisocabtagene maraleucel (liso‐cel) in six RT patients, highlighting the impact of concurrent ibrutinib therapy. Methods Six patients were with RT who received liso‐cel from were included in this single institution case series. Clinical data related to efficacy, safety, CAR‐T expansion kinetics, and measurable residual disease were collected. Results The best overall response was 83.3%. The four patients who received ibrutinib concurrent with liso‐cel therapy continue to show MRD‐negative complete response till date. None experienced severe (grade 3+) cytokine release syndrome while 1 had severe (grade 3+) immune‐effector cell‐associated neurotoxicity syndrome (ICANS). All patients were noted to have in vivo CAR expansion. Conclusion This series of real cases suggests liso‐cel with concurrent ibrutinib may be a promising treatment for RT, warranting further exploration. |
| format | Article |
| id | doaj-art-b3b5ceebb9394d5c981dfe904c70feb3 |
| institution | OA Journals |
| issn | 2688-6146 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | eJHaem |
| spelling | doaj-art-b3b5ceebb9394d5c981dfe904c70feb32025-08-20T02:18:28ZengWileyeJHaem2688-61462025-04-0162n/an/a10.1002/jha2.70011Lisocabtagene Maraleucel for Richter's Transformation—A Case SeriesCourtney J. Smith0Anmol Goyal1Brian R. Smith2Dasom Lee3Alexandria Jensen4Jonathan Alexander5Melody Smith6Matthew Frank7Saurabh Dahiya8David Miklos9Sushma Bharadwaj10Division of Blood and Marrow Transplantation and Cellular Therapy Stanford University School of Medicine Stanford California USADivision of Blood and Marrow Transplantation and Cellular Therapy Stanford University School of Medicine Stanford California USADivision of Blood and Marrow Transplantation and Cellular Therapy Stanford University School of Medicine Stanford California USADivision of Hematology Stanford University School of Medicine Stanford California USAQuantitative Sciences Unit Stanford University School of Medicine Stanford California USADivision of Blood and Marrow Transplantation and Cellular Therapy Stanford University School of Medicine Stanford California USADivision of Blood and Marrow Transplantation and Cellular Therapy Stanford University School of Medicine Stanford California USADivision of Blood and Marrow Transplantation and Cellular Therapy Stanford University School of Medicine Stanford California USADivision of Blood and Marrow Transplantation and Cellular Therapy Stanford University School of Medicine Stanford California USADivision of Blood and Marrow Transplantation and Cellular Therapy Stanford University School of Medicine Stanford California USADivision of Blood and Marrow Transplantation and Cellular Therapy Stanford University School of Medicine Stanford California USAABSTRACT Introduction Richter's transformation (RT) from chronic lymphocytic leukemia (CLL) to lymphoma carries poor prognosis. This case series examines the efficacy of lisocabtagene maraleucel (liso‐cel) in six RT patients, highlighting the impact of concurrent ibrutinib therapy. Methods Six patients were with RT who received liso‐cel from were included in this single institution case series. Clinical data related to efficacy, safety, CAR‐T expansion kinetics, and measurable residual disease were collected. Results The best overall response was 83.3%. The four patients who received ibrutinib concurrent with liso‐cel therapy continue to show MRD‐negative complete response till date. None experienced severe (grade 3+) cytokine release syndrome while 1 had severe (grade 3+) immune‐effector cell‐associated neurotoxicity syndrome (ICANS). All patients were noted to have in vivo CAR expansion. Conclusion This series of real cases suggests liso‐cel with concurrent ibrutinib may be a promising treatment for RT, warranting further exploration.https://doi.org/10.1002/jha2.70011CAR‐T therapyibrutinibRichter's transformation |
| spellingShingle | Courtney J. Smith Anmol Goyal Brian R. Smith Dasom Lee Alexandria Jensen Jonathan Alexander Melody Smith Matthew Frank Saurabh Dahiya David Miklos Sushma Bharadwaj Lisocabtagene Maraleucel for Richter's Transformation—A Case Series eJHaem CAR‐T therapy ibrutinib Richter's transformation |
| title | Lisocabtagene Maraleucel for Richter's Transformation—A Case Series |
| title_full | Lisocabtagene Maraleucel for Richter's Transformation—A Case Series |
| title_fullStr | Lisocabtagene Maraleucel for Richter's Transformation—A Case Series |
| title_full_unstemmed | Lisocabtagene Maraleucel for Richter's Transformation—A Case Series |
| title_short | Lisocabtagene Maraleucel for Richter's Transformation—A Case Series |
| title_sort | lisocabtagene maraleucel for richter s transformation a case series |
| topic | CAR‐T therapy ibrutinib Richter's transformation |
| url | https://doi.org/10.1002/jha2.70011 |
| work_keys_str_mv | AT courtneyjsmith lisocabtagenemaraleucelforrichterstransformationacaseseries AT anmolgoyal lisocabtagenemaraleucelforrichterstransformationacaseseries AT brianrsmith lisocabtagenemaraleucelforrichterstransformationacaseseries AT dasomlee lisocabtagenemaraleucelforrichterstransformationacaseseries AT alexandriajensen lisocabtagenemaraleucelforrichterstransformationacaseseries AT jonathanalexander lisocabtagenemaraleucelforrichterstransformationacaseseries AT melodysmith lisocabtagenemaraleucelforrichterstransformationacaseseries AT matthewfrank lisocabtagenemaraleucelforrichterstransformationacaseseries AT saurabhdahiya lisocabtagenemaraleucelforrichterstransformationacaseseries AT davidmiklos lisocabtagenemaraleucelforrichterstransformationacaseseries AT sushmabharadwaj lisocabtagenemaraleucelforrichterstransformationacaseseries |